Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The UK's National Health Service (NHS) is launching a major trial of blood tests designed to detect 13 different cancers, including bowel, pancreatic, liver and ovarian cancer.

More than 20,000 patients with symptoms like constant bloating or abdominal discomfort are invited to participate in the trial. It spans across more than 200 GP practices in England.

Called STRIDE-RCT, the study is being led by the University of Birmingham and will assess whether three different blood tests can help GPs identify patients who may need further cancer screening sooner.

The tests detect either tiny fragments of DNA released by tumours into the bloodstream or proteins linked with the body's response to cancer.

A single blood sample could provide signals linked with several cancer types and help indicate where the cancer may have originated.

The trial is aimed to determine if certain cancers can be detected early, especially those whose symptoms may overlap with other less serious conditions.

Which 13 Cancers Can The Blood Tests Detect?

Also read: Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy

The trial will examine the tests for their ability to identify these 13 cancers:

1. Bowel cancer
2. Small bowel cancer
3. Stomach cancer
4. Oesophageal cancer
5. Pancreatic cancer
6. Liver cancer
7. Bile duct cancer
8. Gallbladder cancer
9. Ovarian cancer
10. Endometrial cancer
11. Kidney cancer
12. Bladder cancer
13. Prostate cancer

These cancers collectively equal approximately 35,000 deaths each year in England.

The study will evaluate three blood tests. One of them, called Enlighten, was developed by UK biotechnology company Proteotype Diagnostics. It looks for proteins in the blood that indicate the immune system may be responding to early signs of cancer.

Another test, Signatera, is already used by the NHS to monitor whether certain cancers have returned. It detects circulating tumour DNAor fragments of genetic material released by cancer cells into the bloodstream.

Early Detection Of Abdominal Cancers Is Important

Also read: Multicancer Blood Test Detects 17 Cancer In A Large Study: Can It Replace Mammograms & Colonoscopies?

Many abdominal cancers are diagnosed at advanced stages because their early symptoms can be easily mistaken for digestive problems or other common conditions.

Bloating, abdominal discomfort, changes in bowel habits, unexplained weight loss and loss of appetite can have several possible causes. This can make it difficult for patients and doctors to identify cancer early.

According to the trial announcement, around nine in 10 people diagnosed with stage 1 bowel cancer survive for at least five years, compared with approximately one in 10 people diagnosed at stage 4.

Professor Peter Johnson, NHS national clinical director for cancer and chair of the Office for Life Sciences Cancer Goal, said, “Detecting abdomen cancer early is notoriously difficult because the symptoms can easily be mistaken for other less serious conditions, but the NHS is determined to find a solution.”

He added, "We are at the start of revolution in cancer diagnosis, and this trial will help us to find out whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful."

He said it was important to gather evidence about the new technologies and thanked those participating in the research.

Health Secretary Yvette Cooper also highlighted the potential benefits of earlier diagnosis.

"The earlier cancers are diagnosed, the more chance they can be successfully treated and lives can be saved," she said. "This world-first trial will establish whether simple blood tests can help GPs identify much sooner the patients who need urgent support."

The new STRIDE-RCT trial comes after the NHS-Galleri trial, which investigated whether a single blood test could detect multiple cancers before symptoms appeared.

That trial involved more than 142,000 people aged 50 to 77 across England. Participants were randomly assigned to receive either the Galleri blood test alongside usual NHS care or usual care alone.

The Galleri test looks for patterns in tumour DNA circulating in the blood that may signal the presence of cancer.

However, results published in September 2026 showed that the trial did not meet its primary objective of reducing the combined incidence of stage III and stage IV cancers across 12 cancer types. Researchers did observe fewer stage IV cancers, but said further follow-up was needed.

Caring for a cancer patient entails much more than offering emotional support. Family members and loved ones are often tasked with managing medical appointments, monitoring medications, making decisions, handling household responsibilities and navigating financial and legal concerns.

Recognising the challenges faced by these caregivers, the National Comprehensive Cancer Network (NCCN) has issued its first-ever guidelines for people caring for someone with cancer, which is titled NCCN Guidelines for Patients: Caregiving for People with Cancer.

"When a loved one is diagnosed with cancer, naturally, most people want to show up for them however they can. But pretty quickly, many realize it's not just about cancer. They're also juggling everything else in their lives," said Anthea A. Gray, PsyD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, who participated in developing the guide.

"In moments when things feel scary or uncertain—or when everything starts to feel too much—having trusted, easy-to-find information matters a lot," she added. "That is why resources like the NCCN Guidelines for Patients are so helpful. They offer reputable information together in one place, so caregivers can better understand what to expect, make more informed decisions, and support their loved ones with more confidence."

What Do The New NCCN Cancer Caregiver Guidelines Include?

The guidelines cover five major areas of caregiving:

Emotional support

Cancer can affect the emotional well-being of both patients and their caregivers. The guide offers information on supporting a loved one through difficult emotions, uncertainty and the challenges that come with diagnosis and treatment.

Medical management

Caregivers may be expected to help with treatment decisions, manage medications, coordinate medical appointments and perform certain nursing-related tasks at home.

The guide explains what caregivers may need to know, provides information about cancer and its treatment, and suggests questions they can ask healthcare professionals.

Also read: After Olympian Ciara Mageean’s Death At 34, Irish Health Authorities Are Being Urged To Lower Screening Age For Bowel Cancer

Household responsibilities

Managing everyday activities can become difficult when a loved one is undergoing cancer treatment. The guidelines provide practical advice on handling household tasks and organising responsibilities alongside caregiving.

Financial concerns

Cancer treatment can bring additional expenses and financial pressures. The guide addresses financial considerations that caregivers and families may encounter while supporting someone through treatment.

Legal concerns

Caregivers may also need to navigate legal matters while helping a loved one manage their illness. The guidelines include information on legal concerns that may arise during the caregiving process.

The resource also explains common medical terms and concepts to help caregivers better understand a cancer diagnosis and treatment journey.

Cancer Caregivers Need Care Too

The need for caregiver support is growing as more people take on responsibilities for loved ones living with cancer and other chronic illnesses.

According to the 2025 report Caregiving in the US, published by AARP and the National Alliance for Caregiving, approximately 63 million Americans, or nearly one in four adults, provided ongoing care to someone in the previous year.

The NCCN guide also highlights the responsibilities caregivers often manage. At least 70% are balancing employment and other responsibilities, while 60% live separately from the person they care for.

Gray explained that more people are living longer with cancer, sometimes alongside other medical conditions. At the same time, younger people are being diagnosed with cancers, meaning some caregivers are also raising children and working full-time.

"Also, there's a rising number of younger people starting to get cancers that they might not have gotten in the past, and many of these younger people have families, and those caregivers are not only caregivers but maybe parents to young children. Maybe they're working full time," she said.

"So, the landscape of caregiving is changing, and the demands that caregivers once had are increasing."

She also pointed to the financial pressure families face as the cost of everyday expenses rises.

"The increased financial strain that puts on caregivers and families certainly doesn't help the burden that comes along, or can come along, with caregiving," Gray said.

Also read: India Cancer Drug Price Cuts: New Analysis Reveals 159 Out Of 643 Brands See No Reduction

Caregiver Self-Care Guidelines

One of the important points in the new guidelines is their focus on the caregiver's own health.

Caregivers can experience physical exhaustion, emotional distress and financial strain while trying to meet the needs of someone undergoing cancer treatment. Their responsibilities may also leave them with limited time to attend to their own health.

The guide includes a recurring feature called "Caregiver's Corner", which offers self-care information and practical suggestions throughout the book. A separate chapter is dedicated entirely to the caregiver's well-being.

Patrick Delaney, executive director of the NCCN Foundation, said the resource recognises that caregivers also need reliable information to navigate their own journey.

Vitiligo, an autoimmune condition that causes patches of skin to lose pigment, can be difficult to treat. Repigmentation often takes months, and results vary.

Now, two Phase 3 clinical trials, led by an international team of scientists from France, the US and Canada, found that an experimental oral drug, povorcitinib, improved skin pigmentation in adults with moderate-to-severe nonsegmental vitiligo.

What Did The Study Find?

Published in Nature Medicine, the trials STOP-V1 and STOP-V2 involved 916 adults and evaluated once-daily povorcitinib, which blocks JAK1, a protein involved in immune signalling. Key findings include:

• Facial repigmentation: After 52 weeks, 18.9% of patients receiving povorcitinib in both trials achieved at least 75% improvement, compared with 6.8% and 3.1% in the placebo groups.
• Whole-body repigmentation: At least 50% improvement was reported in 18.4% and 12.9% of treated patients, compared with 6.5% and 4.8% in the placebo groups. Only 2.6% and 2.3% achieved at least 75% improvement.
• Disease stabilisation: Exploratory analyses found that 94.3% and 87.6% of treated patients had no increase in disease severity at week 52, compared with 71.8% and 69.2% in the placebo groups.

Are Their Any Safety Concerns?

Overall adverse event rates were broadly similar between the treatment and placebo groups. However, four patients receiving povorcitinib developed basal cell carcinoma, with one case considered treatment-related. One patient experienced blood-clotting complications, including pulmonary embolism and deep vein thrombosis, also considered treatment-related.

Although the findings are encouraging, most patients did not achieve at least 75% facial improvement, and substantial whole-body repigmentation remained uncommon. Longer-term safety data are also needed. Povorcitinib remains investigational and is not yet an established vitiligo treatment.

What Is Vitiligo?

Vitiligo occurs when the immune system attacks melanocytes, the cells responsible for producing skin pigment. Although it is not life-threatening, it can significantly affect emotional and psychological well-being.

Speaking to HealthandMe, Dr Hetanshu Parekh, Consultant Plastic, Reconstructive and Cosmetic Surgeon, Bhailal Amin General Hospital, said vitiligo is more complex than a skin condition alone.

He explained that stress, sleep, diet and skin trauma may influence the disease.

Stress: Stress can disrupt immune balance and increase inflammation, potentially worsening vitiligo. New or expanding patches may appear following major life events, including illness, work pressure or bereavement.

Sleep: Chronic sleep deprivation and irregular sleep schedules may affect immune regulation and potentially worsen autoimmune conditions.

Diet: There is no specific vitiligo diet or food that can cure the condition. Deficiencies in vitamin B12, vitamin D, folate and copper may affect immune and skin health. A balanced diet rich in fruits, vegetables, whole grains, nuts, seeds and omega-3 fatty acids is recommended. Smoking and excessive alcohol consumption should be avoided.

Skin Protection: Friction, cuts, burns and other skin injuries may trigger new patches through a phenomenon known as the Koebner phenomenon. Regular sunscreen use, protective clothing and avoiding repeated skin trauma can help protect the skin.

Is Vitiligo Treatable?

Treatment depends on the extent and stability of the condition.

• Topical medications: Corticosteroid creams and tacrolimus ointment for limited patches.
• Phototherapy: Narrowband UVB and excimer laser to encourage repigmentation.
• Oral medications: Corticosteroids and selected JAK inhibitors for extensive or rapidly spreading disease.
• Surgery: Skin grafting and melanocyte transplantation for selected patients with stable vitiligo.
• Camouflage: Medical tattooing and cosmetic products to conceal patches.